Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease

Neurobiology of Aging

Volumn 33, Issue 5, 2012, Pages 1015.e7-1015.e23

  Erlich, Porat M ^a,c   Lunetta, Kathryn L ^b   Cupples, L Adrienne ^b   Abraham, Carmela R ^a   Green, Robert C ^a,b   Baldwin, Clinton T ^a   Farrer, Lindsay A ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN; PON2 PROTEIN, HUMAN; PON3 PROTEIN, HUMAN;

AFRICAN AMERICAN; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; ASIAN AMERICAN; CAUCASIAN; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ETHNICITY; FEMALE; GENDER; GENE; GENE CLUSTER; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PON1 GENE; PON2 GENE; PON3 GENE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; DRUG POTENTIATION; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; MULTIGENE FAMILY; PHYSIOLOGY; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ARYLDIALKYLPHOSPHATASE; DRUG SYNERGISM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MULTIGENE FAMILY; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 85058205969     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.08.003     Document Type: Article

References (54)

1. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet 1993, 52:598-608.
2. Aydin M., Gencer M., Cetinkaya Y., Ozkok E., Ozbek Z., Kilic G., Orken C., Tireli H., Kara I. PON1 55/192 polymorphism, oxidative stress, type, prognosis and severity of stroke. IUBMB Life 2006, 58:165-172.
3. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., Brennan M.L., Allayee H., Lusis A.J., Hazen S.L. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
4. Boado R.J., Zhang Y., Zhang Y., Wang Y., Pardridge W.M. IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier. Mol. Pharm 2008, 5:1037-1043.
5. Brophy V.H., Hastings M.D., Clendenning J.B., Richter R.J., Jarvik G.P., Furlong C.E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001, 11:77-84.
6. Brophy V.H., Jampsa R.L., Clendenning J.B., McKinstry L.A., Jarvik G.P., Furlong C.E. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet 2001, 68:1428-1436.
7. Browne R.W., Koury S.T., Marion S., Wilding G., Muti P., Trevisan M. Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay. Clin. Chem 2007, 53:310-317.
8. Cellini E., Tedde A., Bagnoli S., Nacmias B., Piacentini S., Bessi V., Bracco L., Sorbi S. Association analysis of the paraoxonase-1 gene with Alzheimer's disease. Neurosci. Lett 2006, 408:199-202.
9. Chapuis J., Boscher M., Bensemain F., Cottel D., Amouyel P., Lambert J.C. Association study of the paraoxonase 1 gene with the risk of developing Alzheimer's disease. Neurobiol. Aging 2009, 30:152-156.
10. Chen J., Chan W., Wallenstein S., Berkowitz G., Wetmur J.G. Haplotype-phenotype relationships of paraoxonase-1. Cancer Epidemiol. Biomarkers Prev 2005, 14:731-734.
11. Dantoine T.F., Debord J., Merle L., Lacroix-Ramiandrisoa H., Bourzeix L., Charmes J.P. Paraoxonase 1 activity: a new vascular marker of dementia?. Ann. N. Y. Acad. Sci 2002, 977:96-101.
12. Dantoine T.F., Drouet M., Debord J., Merle L., Cogne M., Charmes J.P. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann. N.Y. Acad. Sci 2002, 977:239-244.
13. Deakin S., Leviev I., Brulhart-Meynet M.C., James R.W. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem. J 2003, 372:643-649.
14. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res 2005, 46:1239-1247.
15. Erlich P.M., Lunetta K.L., Cupples L.A., Huyck M., Green R.C., Baldwin C.T., Farrer L.A. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum. Mol. Genet 2006, 15:77-85. MIRAGE Study Group.
16. Furlong C.E., Richter R.J., Seidel S.L., Costa L.G., Motulsky A.G. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal. Biochem 1989, 180:242-247.
17. Green R.C., Cupples L.A., Go R., Benke K.S., Edeki T., Griffith P.A., Williams M., Hipps Y., Graff-Radford N., Bachman D., Farrer L.A. Risk of dementia among white and African American relatives of patients with Alzheimer's disease. JAMA 2002, 287:329-336. MIRAGE Study Group.
18. Gaidukov L., Rosenblat M., Aviram M., Tawfik D.S. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J. Lipid. Res 2006, 47:2492-2502.
19. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Ravelli R.B., McCarthy A., Toker L., Silman I., Sussman J.L., Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol 2004, 11:412-419.
20. He X.M., Zhang Z.X., Zhang J.W., Zhou Y.T., Tang M.N., Wu C.B., Hong Z. Gln192Arg polymorphism in paraoxonase 1 gene is associated with Alzheimer disease in a Chinese Han ethnic population. Chin. Med. J. [Engl.] 2006, 119:1204-1209.
21. Janka Z., Juhász A., Rimanóczy A., Boda K., Márki-Zay J., Kálmán J. Codon 311 (Cys -> Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias. Mol. Psychiatry 2002, 7:110-112.
22. Jarvik G.P., Rozek L.S., Brophy V.H., Hatsukami T.S., Richter R.J., Schellenberg G.D., Furlong C.E. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler. Thromb. Vasc. Biol 2000, 20:2441-2447.
23. Khersonsky O., Roodveldt C., Tawfik D.S. Enzyme promiscuity: evolutionary and mechanistic aspects. Curr. Opin. Chem. Biol 2006, 10:498-508.
24. Khersonsky O., Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005, 44:6371-6382.
25. Khersonsky O., Tawfik D.S. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. Chembiochem 2006, 7:49-53.
26. Kim N.S., Kang B.K., Cha M.H., Oh S.M., Ko M.M., Bang O.S. Association between PON1, p5'-regulatory region polymorphisms, PON1 activity and ischemic stroke. Clin. Biochem 2009, 42:857-863.
27. La Du B.N., Adkins S., Kuo C.L., Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem. Biol. Interact 1993, 87:25-34.
28. Leduc V., Poirier J. Polymorphisms at the paraoxonase 1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. Neurodegener. Dis 2008, 5:225-227.
29. Leduc V., Théroux L., Dea D., Robitaille Y., Poirier J. Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology. Eur. J. Neurosci 2009, 30:1823-1830.
30. Leviev I., Righetti A., James R.W. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J. Mol. Med 2001, 79:457-463.
31. Lockridge O., Mottershaw-Jackson N., Eckerson H.W., La Du B.N. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J. Pharmacol. Exp. Ther 1980, 215:1-8.
32. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003, 107:2775-2779.
33. Mackness B., Mackness M.I., Arrol S., Turkie W., Julier K., Abuasha B., Miller J.E., Boulton A.J., Durrington P.N. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998, 139:341-349.
34. Mackness M.I., Harty D., Bhatnagar D., Winocour P.H., Arrol S., Ishola M., Durrington P.N. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991, 86:193-199.
35. McElveen J., Mackness M.I., Colley C.M., Peard T., Warner S., Walker C.H. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem 1986, 32:671-673.
36. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
37. Nozawa M., Tanizawa K., Kanaoka Y. New chromogenic and fluorogenic substrates for the determination of butyrylcholinesterase and arylesterase activities. J. Pharmacobio Dyn 1980, 3:321-327.
38. Paragh G., Balla P., Katona E., Seres I., Egerházi A., Degrell I. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur. Arch. Psychiatry Clin. Neurosci 2002, 252:63-67.
39. Pola R., Flex A., Ciaburri M., Rovella E., Valiani A., Reali G., Silveri M.C., Bernabei R. Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci. Lett 2005, 382:338-341.
40. Pola R., Gaetani E., Flex A., Gerardino L., Aloi F., Flore R., Serricchio M., Pola P., Bernabei R. Lack of association between Alzheimer's disease and Gln-Arg 192 Q/R polymorphism of the PON-1 gene in an Italian population. Dement. Geriatr. Cogn. Disord 2003, 15:88-91.
41. Richter R.J., Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999, 9:745-753.
42. Roccaforte W.H., Burke W.J., Bayer B.L., Wengel S.P. Validation of a telephone version of the mini-mental state examination. J. Am. Geriatr. Soc 1992, 40:697-702.
43. Rosendorff C., Beeri M.S., Silverman J.M. Cardiovascular risk factors for Alzheimer's disease. Am. J. Geriatr. Cardiol 2007, 16:143-149.
44. Saeed M., Perwaiz Iqbal M., Youssuf F.A., Perveen S., Shafiq M., Sajid J., Frossard P.M. Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population. Clin. Genet 2007, 71:238-244.
45. Scacchi R., Gambina G., Martini M.C., Broggio E., Vilardo T., Corbo R.M. Different pattern of association of paraoxonase Gln192->Arg polymorphism with sporadic late-onset Alzheimer's disease and coronary artery disease. Neurosci. Lett 2003, 339:17-20.
46. Shi J., Zhang S., Tang M., Liu X., Li T., Han H., Wang Y., Guo Y., Zhao J., Li H., Ma C. Possible association between Cys311Ser polymorphism of paraoxonase 2 gene and late-onset Alzheimer's disease in Chinese. Brain Res. Mol. Brain Res 2004, 120:201-204.
47. Smolen A., Eckerson H.W., Gan K.N., Hailat N., La Du B.N. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab. Dispos 1991, 19:107-112.
48. Sodeyama N., Yamada M., Itoh Y., Suematsu N., Matsushita M., Otomo E., Mizusawa H. No association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease. Neurology 1999, 53:1146-1148.
49. Stoltz D.A., Ozer E.A., Recker T.J., Estin M., Yang X., Shih D.M., Lusis A.J., Zabner J. A common mutation in paraoxonase-2 results in impaired lactonase activity. J. Biol. Chem 2009, 284:35564-35571.
50. Teiber J.F., Draganov D.I., La Du B.N. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem. Pharmacol 2003, 66:887-896.
51. Wehr H., Bednarska-Makaruk M., Graban A., Lipczyńska-ojkowska W., Rodo M., Bochyńska A., Ryglewicz D. Paraoxonase activity and dementia. J. Neurol. Sci 2009, 283:107-108.
52. Wheeler J.G., Keavney B.D., Watkins H., Collins R., Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004, 363:689-695.
53. Yildiz A., Gur M., Yilmaz R., Demirbag R., Polat M., Selek S., Celik H., Erel O. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008, 197:257-263.
54. Zuliani G., Ble' A., Zanca R., Munari M.R., Zurlo A., Vavalle C., Atti A.R., Fellin R. Genetic polymorphisms in older subjects with vascular or Alzheimer's dementia. Acta. Neurol. Scand 2001, 103:304-308.